MCL Literature Feed

This case report describes a rare CCND1-negative mantle cell lymphoma presenting atypically as leukemia, highlighting the need to consider this diagnosis despite the absence of the classic translocation.

This case series reports an incidental MCL diagnosis from a cervical lymph node during thyroid cancer surgery, underscoring the need for thorough pathological evaluation in atypical presentations.

The CD20xCD3 bispecific antibody glofitamab induces high and durable complete response rates in heavily pretreated relapsed/refractory MCL, providing a new off-the-shelf immunotherapy option post-BTKi failure.

This correspondence provides expert commentary and clarification on the pivotal trial data for the bispecific antibody glofitamab in patients with relapsed/refractory mantle cell lymphoma.

This review clarifies updated WHO-5 diagnostic criteria for high-grade B-cell lymphoma, emphasizing the crucial pathologic and genetic distinction from blastoid mantle cell lymphoma to ensure correct patient management.

This case report describes a rare paraneoplastic syndrome in MCL causing severe thrombocytopenia via both bone marrow failure and immune destruction, which responded to lymphoma-directed chemoimmunotherapy but not standard ITP treatment.

This paper describes a rare MCL variant with an intrasinusoidal bone marrow pattern and prolymphocytoid circulating cells, highlighting an unusual presentation that creates diagnostic challenges for pathologists.

This case report on extranodal marginal zone lymphoma is not relevant to mantle cell lymphoma, as it discusses a different B-cell non-Hodgkin lymphoma subtype.

Mantle cell lymphoma can present with prolymphocytic morphology, a diagnostic pitfall mimicking other lymphoproliferative disorders that requires ancillary testing like cyclin D1 IHC for accurate diagnosis.

This case of clonally-related composite DLBCL and CD5-negative MCL highlights a rare diagnostic challenge, emphasizing the need for comprehensive IHC panels to avoid misdiagnosing transformed lymphoma.

Ibrutinib monotherapy rapidly resolved bilateral intraocular MCL recurrence presenting as pseudo-uveitis and glaucoma, demonstrating its efficacy in this rare CNS sanctuary site relapse.

Genomic analysis of a single MCL patient identified specific mechanisms of resistance to PD-L1 blockade, providing crucial insights into why checkpoint inhibitors are often ineffective in this lymphoma.

This review details the evolution of BTK inhibitors from discovery to clinical use in MCL, covering first-generation agents like ibrutinib and newer agents designed to overcome resistance.

This review summarizes the evolution of BTK inhibitors, highlighting how next-generation agents like pirtobrutinib offer improved selectivity, reduced toxicity, and options to overcome resistance in MCL.

This study validates a method using electronic health records to define real-world progression in MCL, providing a scalable endpoint that correlates strongly with overall survival for evidence generation.

A rare case of co-existing CNS DLBCL and systemic MCL was successfully treated with a multi-modal approach including chemotherapy, ibrutinib bridging, and autologous transplant, achieving 3-year remission.

In high-risk, relapsed/refractory MCL, real-world data shows BTKi plus venetoclax is highly effective, with no added survival benefit from an anti-CD20 monoclonal antibody.

This review summarizes the expanding role of T-cell directing immunotherapies, like bispecifics and CAR-T, in treating relapsed/refractory NHL, providing a framework for their application in MCL.

In a retrospective, mixed-histology study including four MCL patients, splenectomy plus chemotherapy improved survival for aggressive lymphomas presenting with primary splenic involvement, suggesting a potential therapeutic role.

In a prospective cohort of primary GI lymphomas including MCL, routine endoscopic surveillance significantly improved overall survival by detecting relapse early, supporting its role in post-treatment management.

This preclinical study reveals bortezomib, unlike carfilzomib, induces unique multi-organelle stress in endothelial cells, providing a specific mechanism for its cardiovascular toxicity relevant to MCL patients.

Integrated genomic and transcriptomic profiling identifies novel molecular subsets of MCL that predict patient outcomes, paving the way for risk-stratified therapy.

The protein TRIM24 regulates autophagy-mediated resistance to the proteasome inhibitor bortezomib, offering a potential new therapeutic target to overcome drug resistance in relapsed/refractory MCL.

A new CAR-T hematotoxicity score developed for B-ALL, which replaces ferritin with bone marrow burden, highlights the need to refine existing models like CAR-HT used in MCL for disease-specific prediction.

This retrospective Chinese study validates POD24 (progression within 24 months) as a powerful negative prognostic marker and incorporates it into a new model to better risk-stratify relapsed patients.

Alternating R-DA-EDOCH/R-DHAP induction for young, newly diagnosed MCL patients achieved an 89% complete remission rate and high MRD negativity, offering a potent new frontline intensive chemotherapy option.

A case of Candida albicans meningoencephalitis in an MCL patient highlights the diagnostic challenge of CNS symptoms, underscoring the need to consider opportunistic fungal infections beyond CNS relapse.

In a small real-world study of 38 relapsed/refractory MCL patients, zanubrutinib was associated with fewer select adverse events like hypertension and hemorrhage compared to acalabrutinib.

This case series identifies a rare intrasinusoidal bone marrow involvement pattern in MCL, highlighting a key diagnostic pitfall for pathologists and expanding the disease's recognized histopathological spectrum.

Combining acalabrutinib with bendamustine-rituximab is safe and highly active, achieving a 78% complete response rate and unreached median progression-free survival at 47.6 months in treatment-naive mantle cell lymphoma.